R-IDARAM treatment in central nervous system lymphomas: a single-center experience and review of the literature

Introduction: Central nervous system lymphomas (CNSLs) require effective treatment strategies due to aggressive nature of disease. Despite therapeutic approaches having improved in the last decades, there is no standard treatment for these patients. As a CNSL targeted-therapy IDARAM protocol was dev...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Senem Maral, Murat Albayrak, Cigdem Pala, Abdulkerim Yıldız, Hacer B Ozturk, Osman Sahin
Formato:	article
Lenguaje:	EN
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2020
Materias:	aggressive lymphomas central nervous system lymphomas modified r-idaram Medicine R
Acceso en línea:	https://doaj.org/article/3ce37d5ea085439b99c8ecbe3e7808d8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3ce37d5ea085439b99c8ecbe3e7808d8
record_format	dspace
spelling	oai:doaj.org-article:3ce37d5ea085439b99c8ecbe3e7808d82021-12-02T19:01:54ZR-IDARAM treatment in central nervous system lymphomas: a single-center experience and review of the literature2231-07702249-446410.4103/ajm.ajm_59_19https://doaj.org/article/3ce37d5ea085439b99c8ecbe3e7808d82020-10-01T00:00:00Zhttp://www.thieme-connect.de/DOI/DOI?10.4103/ajm.ajm_59_19https://doaj.org/toc/2231-0770https://doaj.org/toc/2249-4464Introduction: Central nervous system lymphomas (CNSLs) require effective treatment strategies due to aggressive nature of disease. Despite therapeutic approaches having improved in the last decades, there is no standard treatment for these patients. As a CNSL targeted-therapy IDARAM protocol was developed, the outcomes were reported with a few studies. We observed the R-IDARAM protocol in our CNSL cases, and we discuss the effectiveness, tolerability, and toxicity with a review of the literature in this article. Subjects and Methods: We retrospectively analyzed response rates, progression-free survival, adverse events, and long-term side effects in patients who were treated by modified R-IDARAM as standard clinical care of CNSL in our hematology department. Results: Response was achieved in five of nine patients. Three patients (two primary CNSL and one secondary CNSL) are still being followed up without disease progression with a median duration of follow-up of 79 months (88, 79, and 17 months, respectively). Manageable hematological side effects including thrombocytopenia and neutropenia were experienced by all patients. Conclusion: R-IDARAM protocol may be an option with high early response rates and manageable toxicity. Hematological side effects are the main problem, and long-term neurological toxicity is not common. Eligible patients must continue with autologous stem cell transplantation due to poor long-term survival outcomes.Senem MaralMurat AlbayrakCigdem PalaAbdulkerim YıldızHacer B OzturkOsman SahinThieme Medical and Scientific Publishers Pvt. Ltd.articleaggressive lymphomascentral nervous system lymphomasmodified r-idaramMedicineRENAvicenna Journal of Medicine, Vol 10, Iss 04, Pp 227-231 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	aggressive lymphomas central nervous system lymphomas modified r-idaram Medicine R
spellingShingle	aggressive lymphomas central nervous system lymphomas modified r-idaram Medicine R Senem Maral Murat Albayrak Cigdem Pala Abdulkerim Yıldız Hacer B Ozturk Osman Sahin R-IDARAM treatment in central nervous system lymphomas: a single-center experience and review of the literature
description	Introduction: Central nervous system lymphomas (CNSLs) require effective treatment strategies due to aggressive nature of disease. Despite therapeutic approaches having improved in the last decades, there is no standard treatment for these patients. As a CNSL targeted-therapy IDARAM protocol was developed, the outcomes were reported with a few studies. We observed the R-IDARAM protocol in our CNSL cases, and we discuss the effectiveness, tolerability, and toxicity with a review of the literature in this article. Subjects and Methods: We retrospectively analyzed response rates, progression-free survival, adverse events, and long-term side effects in patients who were treated by modified R-IDARAM as standard clinical care of CNSL in our hematology department. Results: Response was achieved in five of nine patients. Three patients (two primary CNSL and one secondary CNSL) are still being followed up without disease progression with a median duration of follow-up of 79 months (88, 79, and 17 months, respectively). Manageable hematological side effects including thrombocytopenia and neutropenia were experienced by all patients. Conclusion: R-IDARAM protocol may be an option with high early response rates and manageable toxicity. Hematological side effects are the main problem, and long-term neurological toxicity is not common. Eligible patients must continue with autologous stem cell transplantation due to poor long-term survival outcomes.
format	article
author	Senem Maral Murat Albayrak Cigdem Pala Abdulkerim Yıldız Hacer B Ozturk Osman Sahin
author_facet	Senem Maral Murat Albayrak Cigdem Pala Abdulkerim Yıldız Hacer B Ozturk Osman Sahin
author_sort	Senem Maral
title	R-IDARAM treatment in central nervous system lymphomas: a single-center experience and review of the literature
title_short	R-IDARAM treatment in central nervous system lymphomas: a single-center experience and review of the literature
title_full	R-IDARAM treatment in central nervous system lymphomas: a single-center experience and review of the literature
title_fullStr	R-IDARAM treatment in central nervous system lymphomas: a single-center experience and review of the literature
title_full_unstemmed	R-IDARAM treatment in central nervous system lymphomas: a single-center experience and review of the literature
title_sort	r-idaram treatment in central nervous system lymphomas: a single-center experience and review of the literature
publisher	Thieme Medical and Scientific Publishers Pvt. Ltd.
publishDate	2020
url	https://doaj.org/article/3ce37d5ea085439b99c8ecbe3e7808d8
work_keys_str_mv	AT senemmaral ridaramtreatmentincentralnervoussystemlymphomasasinglecenterexperienceandreviewoftheliterature AT muratalbayrak ridaramtreatmentincentralnervoussystemlymphomasasinglecenterexperienceandreviewoftheliterature AT cigdempala ridaramtreatmentincentralnervoussystemlymphomasasinglecenterexperienceandreviewoftheliterature AT abdulkerimyıldız ridaramtreatmentincentralnervoussystemlymphomasasinglecenterexperienceandreviewoftheliterature AT hacerbozturk ridaramtreatmentincentralnervoussystemlymphomasasinglecenterexperienceandreviewoftheliterature AT osmansahin ridaramtreatmentincentralnervoussystemlymphomasasinglecenterexperienceandreviewoftheliterature
_version_	1718377258998038528

R-IDARAM treatment in central nervous system lymphomas: a single-center experience and review of the literature

Ejemplares similares